Uncategorized Archives - Page 93 of 112

MondayAug 06, 2018 10:04 am

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) to Launch OKI Brand CBD-Infused Products in 3Q2018, Signs Agreement for Access to 2,400 Stores

PHVAF inks agreement with Acosta’s National Specialty Sales division to sell to 2,400 retailers across U.S., will later have access to 25,000 more supermarkets, such as Wal-Mart and Target Jim Bailey, PHVAF CEO and president, terms crossover distribution into mainstream national retailers a “significant milestone” for the CBD industry; market channel is valued at $4.1 billion OKI line to consist of CBD-infused beverages, such as iced tea and flavored infused waters, plus tinctures and capsules; it will be available to consumers in 3Q2018 Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) will launch its OKI brand of premium CBD products to…

FridayAug 03, 2018 1:58 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enabling Companies to Produce High-Quality Cannabis-Infused Products

80 percent of the company’s total revenue anticipated from the licensing of DehydraTECH™ Nuke Enterprises renewed its license, sending a strong vote of confidence in the technology Enabled GP Holdings to create a high-performing cannabis-infused beverage Biolog Inc. is developing products which will allow processors and consumers to turn almost any food or beverage into a cannabis edible Beginning production of a line of cannabis-infused alcohol-free beverages through a new licensing agreement Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a drug delivery platform innovator, utilizes its unique patented DehydraTECH™ delivery technology to enhance the products of its clients. This patented…

FridayAug 03, 2018 11:52 am

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advances Controlled Synthesis of Scorpion Venom Peptides for Brain Therapies

PreveCeutical’s ‘Nature Identical™’ efforts aim to create consistently reproducible versions of found-in-nature therapeutics Company has begun engineering redesign phase of select identified peptides derived from famed scorpion venom Preventative therapeutics market expected to generate $196.9 billion in revenues by 2024, demonstrating alternative health products’ potential PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) efforts to develop a synthesized and consistently reproducible ‘Nature Identical™’ scorpion venom, popular as a pain reliever and cancer therapy, has taken a new step toward marketability as the company commences work on re-engineering venom peptide components to stabilize them. The biotech company based in British…

ThursdayAug 02, 2018 2:15 pm

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Subsidiary Inks Another Supply Contract for Upcoming Cannabis Crop

Operating in world’s two largest cannabis markets – California and Canada Cannabis concentrate extraction service agreement inked with Cannabis Strategic Venture subsidiary Pure Applied Sciences, Inc. to provide white label services of high quality, ultra-purified cannabis extracts Construction underway in California and Canada of large scale, purpose-built current cGMP designed greenhouses for cannabis cultivation and production Supply agreement with Canopy Growth Corporation to provide up to 90,000 kg of cannabis over two years beginning in early 2019 Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF), a vertically integrated medical cannabis company headquartered in Vancouver, Canada, is committed to delivering safe, consistent, high-quality products and…

ThursdayAug 02, 2018 12:11 pm

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) is “One to Watch”

Publicly traded on the Canadian Securities Exchange (CSE.VIDA) and recently graduated to the OTCQX Best Market in the USA (OTCQX.PHVAF) Strong balance sheet and capital structure with over CAD $15.5 million cash, no debt, with less than 60 million shares outstanding – fully capitalized for global distribution Expert management team includes former senior executives from Red Bull, Proctor & Gamble, Labatt’s, Stoli Group and the former CEO of Seagram’s International Joint venture with top Canadian licensed producer WeedMD (TSX: WMD) for one of the first federally legal cannabis beverage manufacturing facility, new global distribution partners Developing best-in-class premium CBD-hemp oil…

MondayJul 30, 2018 1:33 pm

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) Signs Cannabis Extraction Deal with Cannabis Strategic Ventures (OTC: NUGS)

Sunniva’s CP Logistics to produce ultra-purified extracts under Cannabis Strategic Ventures’ Pure Organix™ brand Investment banking firm Canaccord Genuity initiates coverage of Sunniva Canaccord Genuity gives Sunniva positive share price valuation above current market performance and a “speculative buy” rating Vertically integrated cannabis company Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) has announced an agreement to produce top-quality cannabis extracts for Cannabis Strategic Ventures, Inc. (OTC: NUGS) (http://cnw.fm/B3aVh). Under the white label services agreement, Sunniva’s CP Logistics (“CPL”) subsidiary will produce ultra-purified cannabis extracts for the Pure Organix™ brand, owned by Cannabis Strategic’s subsidiary, Pure Applied Sciences, Inc. From its Sun-Oil Facility in Cathedral…

FridayJul 27, 2018 12:46 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Establishes Business Unit for $55 Billion Medical Marijuana Market

Medical indications for marijuana multiply Medical marijuana (MMJ) market moves mainstream New cannabis business unit to focus on MMJ market Now that some 44 nations around the globe have passed laws allowing marijuana for medical use, the market is set for rapid expansion in the coming years. Industry analysts Grand View Research estimate that the global medical marijuana market will reach a value of $55.8 billion by 2025, as the range of therapies for cannabis multiplies (http://cnw.fm/8dEr3). Much of this expected demand will be driven by treatments for chronic pain, but applications are also likely to be developed for a number of other…

ThursdayJul 26, 2018 12:41 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH May Play Larger Role in Treating Nervous System Disorders and Diseases

LXRP files for patent with the USPTO for DehydraTECH’s innovative treatment options for diseases and disorders including Alzheimer’s, Huntington’s and Parkinson’s Company hopes to leverage this future possible patent to commercialize its development or out-licensing of future new products that treat central nervous system diseases DehydraTECH platform, being lab tested for drug delivery, effectively transported nicotine across the blood brain barrier, a barrier that protects the brain and makes traditional treatment difficult Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has already received some eight patents granted and nearly 50 pending worldwide, and the company has…

WednesdayJul 25, 2018 12:46 pm

PreveCeutical Medical’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Breakthrough Sol-gel Drug Delivery Platform Featured in Proactive Investors Interview

PreveCeutical was recently featured in an interview by Proactive Investors The company is currently developing its Sol-gel drug delivery platform for delivery of cannabinoids Sol-gel technology is paving the way for direct nose-to-brain drug delivery Innovative health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was recently featured by Proactive Investors in a “Corporate News Update” regarding the company’s potentially game-changing Sol-gel drug delivery platform (http://cnw.fm/Xm1tL). The company earlier provided a written press release updating the Sol-gel program (http://cnw.fm/L2Lxb). Sol-gel, a nickname for soluble gel, is taken through nasal (systemic) administration and quickly gels once it comes in…

TuesdayJul 24, 2018 1:58 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Applicable to Multiple Industries

Active investigation phase in the EU, Canada, China, Japan and India Forming four new wholly owned subsidiaries Seeks to acquire an equitable tax treatment Cannabinoids are poorly absorbed by the body’s gastrointestinal tract, a trait that Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) lipophilic enhancement technology DehydraTECH™ is changing. Previously, consumers have turned to cannabis smoking to achieve higher effectiveness. However, human clinical studies have shown DehydraTECH™ to have a quick rate of absorption, allowing users to avoid the risks associated with smoking. DehydraTECH™ offers improved taste and smell, with effects felt within 15 to 20 minutes as opposed to…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000

Category: Uncategorized